当前位置:

网站首页>文章详情

基因检测与个体化抗血小板治疗相关研究进展

【PDF在线阅读】 【下载PDF】
  • Author:

  • Author Unit:

  • 关键词:

  • Keywords:

  • 中图分类号:

  • R541

摘要:

Abstract:

基金项目:

参考文献:

[1] Valgimigli M,Bueno H,Byrne RA,et al. 2017 ESC focused update
on dual antiplatelet therapy in coronary artery disease developed
in collaboration with EACTS: The Task Force for dual antiplatelet
therapy in coronary artery disease of the European Society of
Cardiology (ESC) and of the European Association for Cardio-
Thoracic Surgery (EACTS)[J]. Eur Heart J,2018,39(3):213-60.
[2] Wallentin L,Becker RC,Budaj A,et al. Ticagrelor versus clopidogrel in
patients with acute coronary syndromes[J]. N Engl J Med,2009,361(11):
1045-57.
[3] Wiviott SD,Braunwald E,McCabe CH,et al. Prasugrel versus
clopidogrel in patients with acute coronary syndromes [J]. N Engl J
Med,2007,357(20):2001-15.
[4] Tuteja S,Limdi N. Pharmacogenetics in Cardiovascular Medicine[J].
Curr Genet Med Rep,2016,4(3):119-29.
[5] Gurbel PA,Becker RC,Mann KG,et al. Platelet function monitoring in
patients with coronary artery disease [J]. J Am Coll Cardiol,2007,50
(19):1822-34.
[6] 钟诗龙,韩雅玲,陈纪言,等. 氯吡格雷抗血小板治疗个体化用药基
因型检测指南解读[J]. 中国实用内科杂志,2015,(1):38-41.
[7] Miao J,Liu R,Li Z. Cytochrome P-450 polymorphisms and response
to clopidogrel[J]. N Engl J Med,2009,360(21):2250-1.
[8] Simon T,Verstuyft C,Mary-Krause M,et al. Genetic determinants
of response to clopidogrel and cardiovascular events[J]. N Engl J
Med,2009,360(4):363-75.
[9] Sugimoto K,Uno T,Yamazaki H,et al. Limited frequency of the
CYP2C19*17 allele and its minor role in a Japanese population[J]. Br
J Clin Pharmacol,2008,65(3):437-9.
[10] Nagashima Z,Tsukahara K,Morita S,et al. Platelet reactivity in the
early and late phases of acute coronary syndromes according to
cytochrome P450 2C19 phenotypes[J]. J Cardiol,2013,62(3):158-64.
[11] Osnabrugge RL,Head SJ,Zijlstra F,et al. A systematic review and
critical assessment of 11 discordant meta-analyses on reducedfunction
CYP2C19 genotype and risk of adverse clinical outcomes in
clopidogrel users [J]. Genet Med, 2015,17(1):3-11.
[12] Holmes MV,Perel P,Shah T,et al. CYP2C19 genotype,clopidogrel
metabolism, platelet function, and cardiovascular events: a systematic
review and meta-analysis [J]. Jama,2011,306(24):2704-14.
[13] Collet JP,Hulot JS,Pena A,et al. Cytochrome P450 2C19 polymorphism
in young patients treated with clopidogrel after myocardial infarction:a
cohort study [J]. Lancet,2009,373(9660):309-17.
[14] Zabalza M,Subirana I,Sala J,et al. Meta-analyses of the association
between cytochrome CYP2C19 loss- and gain-of-function
polymorphisms and cardiovascular outcomes in patients with coronary
artery disease treated with clopidogrel[J]. Heart,2012,98(2):100-8.

[15] Angiolillo DJ,Ferreiro JL,Price MJ,et al. Platelet function and genetic

testing[J]. J Am Coll Cardiol,2013,62(17 Suppl):S21-31.
[16] Notarangelo FM,Maglietta G,Bevilacqua P,et al. Pharmacogenomic
Approach to Selecting Antiplatelet Therapy in Patients With Acute
Coronary Syndromes: The PHARMCLO Trial[J]. J Am Coll Cardiol,
2018,71(17):1869-77.
[17] Cavallari LH,Lee CR,Beitelshees AL,et al. Multisite Investigation
of Outcomes With Implementation of CYP2C19 Genotype-Guided
Antiplatelet Therapy After Percutaneous Coronary Intervention[J].
JACC Cardiovasc Interv,2018,11(2):181-91.
[18] Hochholzer W,Ruff CT,Mesa RA,et al. Variability of individual
platelet reactivity over time in patients treated with clopidogrel:
insights from the ELEVATE-TIMI 56 trial[J]. J Am Coll Cardiol,
2014,64(4):361-8.
[19] Mega JL,Hochholzer W,Frelinger AL,et al. Dosing clopidogrel based
on CYP2C19 genotype and the effect on platelet reactivity in patients
with stable cardiovascular disease[J]. Jama,2011,306(20):2221-8.
[20] Pereira NL,Sargent DJ,Farkouh ME,et al. Genotype-based clinical
trials in cardiovascular disease[J]. Nat Rev Cardiol,2015,12(8):475-87.
[21] Bergmeijer TO,Janssen PW,Schipper JC,et al. CYP2C19 genotypeguided
antiplatelet therapy in ST-segment elevation myocardial
infarction patients-Rationale and design of the Patient Outcome
after primary PCI (POPular) Genetics study[J]. Am Heart
J,2014,168(1):16-22.e11.
[22] Varenhorst C,Eriksson N,Johansson A,et al. Effect of genetic
variations on ticagrelor plasma levels and clinical outcomes[J]. Eur
Heart J,2015,36(29):1901-12.

  • 2008

  • 1

通讯地址:北京市东城区东四十条南门仓5号
电话: 237499284 邮编:100700
网址:www.ebcvm..org Email: ebcvm_cj@126.com

copyright © 《中国循证心血管医学杂志》编辑部
当您在使用本网站投稿遇到困难时,
请直接将稿件投送到编辑部邮箱ebcvm_cj@126.com